-
In 2023, the pace of mergers and acquisitions by multinational pharmaceutical companies may accelerate, targeting two hundred billion US dollar markets
Time of Update: 2023-02-01
Looking back on 2022, although the popularity of acquisitions in the pharmaceutical industry has decreased compared with the previous year, it is still remarkable. According to the 2022 pharmaceutica
-
Recently, there has been good news in the field of anti-tumor drugs, involving clinical and marketing...
Time of Update: 2023-02-01
The company's cyclophosphamide capsules (25mg) were included in the priority review and approval process in October 2021, and the approval of both specifications (25mg and 50mg) is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs.
-
R&D investment continues to increase, and the modernization of Chinese medicine is accelerating
Time of Update: 2023-02-01
In addition, in recent years, Yiling Pharmaceutical is also making full use of the methods and means of modern science and technology to continuously increase investment in scientific research and leapfrog development of innovative Chinese medicine drugs on the basis of inheriting and carrying forward the advantages and characteristics of traditional Chinese medicine.
-
Last year, the province added more than 50 national Class 1 new drugs, children's rare disease drugs, and first generic drugs
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];With a series of "warm government" incentives, the innovation vitality of Hubei's biomedical industry has been significantly enhanced.
js?cdnversion='+~(-new Date()/36e5)];With a series of "warm government" incentives, the innovation vitality of Hubei's biomedical industry has been significantly enhanced.
-
The era of dental implants is coming to an end? The price of imported brands dropped to more than 100 yuan
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search.
js?cdnversion='+~(-new Date()/36e5)];On January 12, the topic of "the era of 10,000 yuan of dental implants is coming to an end" appeared on the hot search.
-
A number of pharmaceutical companies have achieved good results, and Huahai Pharmaceutical's net profit has doubled
Time of Update: 2023-02-01
Jiudian Pharmaceutical also released a performance forecast on the evening of January 15, saying that it is expected that the net profit attributable to shareholders of listed companies in 2022 will be 263 million yuan ~ 273 million yuan, a year-on-year increase of 28.
-
In 2023, the scale of China's pharmaceutical packaging market will exceed 150 billion, and domestic leading enterprises will attract investors' attention
Time of Update: 2023-02-01
Domestic head enterprises attract the attention of investors At present, in the context of the continuous expansion of the domestic pharmaceutical packaging market, the industry believes that domestic pharmaceutical packaging material companies are also expected to usher in development opportunities and accelerate the pace of domestic substitution.
-
In 2022, the medical device industry will continue to grow rapidly, and the operating income is expected to reach 1.3 trillion yuan
Time of Update: 2023-02-01
Analysts pointed out that benefiting from the development of the economic level, the health demand is increasing, and China's medical device market has ushered in huge development opportunities. Thro
-
There are long-term development opportunities in the traditional Chinese medicine sector, and there are huge investment opportunities in these three segments in 2023
Time of Update: 2023-02-01
Planting and primary processing of Chinese medicinal materials Recently, the State Food and Drug Administration issued Several Measures on Further Strengthening the Scientific Supervision of Chinese Medicines and Promoting the Inheritance, Innovation and Development of Chinese Medicines, which mentioned that the supervision and inspection of Chinese medicine tablets, Chinese medicine formula granules and proprietary Chinese medicines should be continuously strengthened, and the extended inspection of Chinese medicinal materials should be carried out in an orderly manner.
-
Letter soliciting comments on the draft general rules and supporting general testing methods for plastic containers and components for pharmaceutical packaging under the Chinese Pharmacopoeia (first batch).
Time of Update: 2023-02-01
Source: National Pharmacopoeia Commission Time: 2023-01-16 10:43:54 Print Related: According to the work plan, our committee organized and drafted 5 general rules related to plastic containers and components for pharmaceutical packaging and 9 draft supporting general testing methods (see Annex 1-6), and is now soliciting relevant opinions on the draft standard.
-
After the implementation of "Class B and B tube", what is the situation of severe treatment nationwide?
Time of Update: 2023-02-01
Good medical treatment is the key to responding to the epidemic after the implementation of "Class B and B tube". By optimizing processes, expanding resources, and increasing strength, China has stre
-
In the past week, a large number of pharmaceutical companies have obtained drug registration certificates!
Time of Update: 2023-02-01
News on January 13, Huaren Pharmaceutical said that it recently received the "Drug Registration Certificate" of "sodium bicarbonate Ringer injection" approved and issued by the National Medical Products Administration.
-
Heavy! The eighth batch of national procurement reporting documents involved 41 varieties and 181 product specifications
Time of Update: 2023-02-01
Appendix 1: Fill in the report of relevant drug procurement demand Appendix 2: The current competitive pattern of the eighth batch of centralized procurement varieties Data sources: NMPA, pharmacointelligence dataPS: The data is manually statistically collated, if there is a missing data, please understand, but also please correct in the comment area, thank you!If this article violates your rights, please contact us.
-
Hundreds of millions of discounted interest loans help mass spectrometer procurement! Last month, the total amount of the mass spectrometer won the bid exceeded 1.1 billion
Time of Update: 2023-02-01
On September 7, 2022, the executive meeting of the State Council decided to impose a 2. 5% financial discount on loans for equipment renovation and renovation in some fields before December 31, and o
-
China's domestic small molecule new coronavirus treatment is undergoing clinical trials
Time of Update: 2023-02-01
drugs In the 10th edition of the new coronavirus infection diagnosis and treatment plan announced in China, antiviral treatment includes nematevir tablets/ritonavir tablets combination package (referred to as "Paxlovid"), azvudine tablets, monoclonal antibodies, intravenous COVID-19 human immunoglobulin, convalescent plasma of convalescent patients, etc.
-
National Bureau of Statistics: Hog prices fell 10.7% month-on-month in early January
Time of Update: 2023-02-01
According to the monitoring of the market prices of 50 important means of production in 9 categories in the national circulation field, compared with the end of December 2022, 21 products rose in price, 27 decreased, and 2 remained flat.
-
At the beginning of the new year, many pharmaceutical companies have begun to look forward to 2023 performance!
Time of Update: 2023-02-01
. In addition, Guizhou Sanli is expected to achieve a net profit attributable to the owner of the parent company of 196 million yuan ~ 217 million yuan in 2022, an increase of 43.
-
In 2023, the willingness of domestic innovative drugs to go overseas will continue to increase
Time of Update: 2023-02-01
In 2023, the willingness of domestic innovative drugs to go overseas will continue to increase (Image source; Pharma Network) Domestic innovation strength is increasingly recognized, and going overseas is accelerating Some time ago, Kelun Pharmaceutical reached an overseas rights authorization with Merck for 7 preclinical ADC drugs, with a total milestone of up to US$9.
-
Affected by the surge in demand for Paxlovid, Pfizer is ready to start production in China
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];A few days ago, Pfizer CEO Aberle said that the surge in demand for Paxlovid in the Chinese market has led to tight supply, and it is working with a Chinese contract drugmaker to prepare for local production.
-
In 2022, 20 FIC therapies will be approved by the FDA, covering HIV, diabetes and other indications
Time of Update: 2023-02-01
Pluvicto Novartis' Pluvicto was approved by the US FDA in March 2022 for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received taxane-based chemotherapy and androgen receptor signaling pathway inhibitors.
